BAYER FACES FOURTH U.S. ROUNDUP CANCER TRIAL
(Reuters) - Bayer AG (BAYGn.DE) is set to face a fourth U.S. jury trial over allegations that its Roundup weed killer causes cancer, with four cancer patients in the hometown of its agricultural subsidiary Monsanto scheduled to begin making their case on Friday.
The lawsuit marks the first multi-plaintiff trial in the litigation over whether glyphosate, Roundup’s active ingredient, is carcinogenic, and is the first trial outside of California. It is being held in St. Louis, where Monsanto was headquartered before Bayer bought the company in a $63 billion deal in 2018.